Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00444743
Status:
COMPLETED
Last Update Posted:
2008-12-18
First Post:
2007-03-07
Brief Title:
Phase 2 Study of MM-093 to Treat Patients With Uveitis
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Study Overview
Official Title:
A Phase 2 Double - Blind Placebo - Controlled Randomized Study to Evaluate the Tolerability Pharmacokinetics Pharmacodynamics and Biologic Activity of MM-093 in Patients With Moderate to Severe Uveitis
Status:
COMPLETED
Status Verified Date:
2008-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the tolerability pharmacokinetics pharmacodynamics and biologic activity of MM-093 in patients with moderate to severe uveitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IND 100184 | None | None | None |